AI In Drug Repurposing Market Size, Share & Trends Analysis Report By Component, By Technology, By Application, By End Use, By Region, And Segment Forecasts, 2025 - 2033

PUBLISHED: September 29, 2025

PAGES: 100 Pages

DELIVERY TIME: 2-10 business days

ADD TO COMPARE

SELECT AN OPTION

The global AI in drug repurposing market size was estimated at USD 1.02 billion in 2024 and is projected to reach USD 5.48 billion by 2033, growing at a CAGR of 20.39% from 2025 to 2033. Rising demand for cost-effective drug development, advancements in AI algorithms, and the growing prevalence of rare and complex diseases are significant factors contributing to market growth.

In addition, increasing collaborations between pharmaceutical companies, academic institutions, and AI technology providers, and improvements in computing power and cloud infrastructure are some other factors fueling the growth.

The rising demand for cost-effective drug development strategies substantially drives the growth of the AI in drug repurposing industry. Traditional drug discovery involves lengthy timelines, often exceeding a decade, and costs frequently exceed USD 2 billion per drug. Drug repurposing offers a strategy to bypass early-stage safety testing by focusing on approved or investigational drugs for new indications. AI accelerates this process by rapidly analyzing extensive biological, chemical, and clinical datasets to identify novel drug-disease associations. This reduces development timelines and costs, offering pharmaceutical companies and healthcare providers an economically viable alternative to de novo drug development. Integrating artificial intelligence with drug repurposing effectively addresses key industry challenges by enhancing productivity while reducing associated risks and investments.

AI systems integrate multi-omics data, including genomics, proteomics, and metabolomics, with biomedical literature and real-world patient records to identify subtle and previously unrecognized drug-target interactions. These methods enable the identification of polypharmacology candidates and synergistic drug combinations, overcoming limitations of traditional hypothesis-driven discovery. For instance, in April 2025, Plex Research partnered with Ginkgo Bioworks to use AI-powered analysis on the GDPx2 dataset, a large transcriptomics survey of compound-induced gene expression. This collaboration aims to identify novel disease mechanisms, discover new therapeutic applications, and accelerate drug repurposing, linking findings with experimental data for rigorous validation.

Furthermore, the rising prevalence of rare diseases propels market growth further. For instance, according to the data published by The Lancet Journal in March 2024, around 300 million people live with rare diseases, affecting around 3.5% - 5.9% of the global population. Moreover, around 80% of rare diseases are genetically caused, almost 70% of which are present in childhood. AI facilitates the analysis of limited datasets from rare disease cohorts, enabling the identification of therapeutic candidates from existing drugs, thus expediting treatment access.

Global AI In Drug Repurposing Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global AI in drug repurposing market report based on component, technology, application, end use, and region:

Component Outlook (Revenue, USD Million, 2021 - 2033)
Software & Platforms
Services
Technology Outlook (Revenue, USD Million, 2021 - 2033)
Machine Learning/Deep Learning
Natural Language Processing (NLP)
Knowledge Graphs & Network-Based AI
Generative AI & Large Language Models (LLMs)
Computer Vision
Application Outlook (Revenue, USD Million, 2021 - 2033)
Oncology
Neurology
Cardiology
Infectious Diseases
Rare & Orphan Diseases
Other Therapeutic Areas
End Use Outlook (Revenue, USD Million, 2021 - 2033)
Pharmaceutical & Biotechnology Companies
Contract Research Organizations (CROs)
Academic & Research Institutes
Others
Regional Outlook (Revenue, USD Million, 2021 - 2033)
North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- UK
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Thailand
Latin America
- Brazil
- Argentina
MEA
- South Africa
- Saudi Arabia
- UAE
- Kuwait

Product Code: GVR-4-68040-755-3

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope
1.2. Market Definitions
- 1.2.1. Component Segment
- 1.2.2. Technology Segment
- 1.2.3. Application Segment
- 1.2.4. End Use
1.3. Information analysis
- 1.3.1. Market formulation & data visualization
1.4. Data validation & publishing
1.5. Information Procurement
- 1.5.1. Primary Research
1.6. Information or Data Analysis
1.7. Market Formulation & Validation
1.8. Market Model
1.9. Total Market: CAGR Calculation
1.10. Objectives
- 1.10.1. Objective 1
- 1.10.2. Objective 2

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Insights Landscape

Chapter 3. AI in Drug Repurposing Market Variables, Trends & Scope

3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook.
3.2. Market Dynamics
- 3.2.1. Market driver analysis
  - 3.2.1.1. Rising demand for cost-effective drug development,
  - 3.2.1.2. Advancements in AI algorithms
  - 3.2.1.3. Increasing collaborations between pharmaceutical companies, academic institutions, and AI technology providers,
- 3.2.2. Market restraint analysis
  - 3.2.2.1. Data security and privacy concerns
  - 3.2.2.2. High computational costs and infrastructure requirements
- 3.2.3. Market opportunity analysis
- 3.2.4. Market challenges analysis
3.3. AI in Drug Repurposing Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
  - 3.3.1.1. Supplier power
  - 3.3.1.2. Buyer power
  - 3.3.1.3. Substitution threat
  - 3.3.1.4. Threat of new entrant
  - 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
  - 3.3.2.1. Political landscape
  - 3.3.2.2. Technological landscape
  - 3.3.2.3. Economic landscape
  - 3.3.2.4. Environmental Landscape
  - 3.3.2.5. Legal Landscape
  - 3.3.2.6. Social Landscape
3.4. Case Studies
3.5. Technology Analysis: Key Use Cases and Application
- 3.5.1. Machine Learning (ML)/Deep Learning
- 3.5.2. Natural Language Processing (NLP)
- 3.5.3. Generative AI & Large Language Models (LLMs)

Chapter 4. AI in Drug Repurposing Market: Component Estimates & Trend Analysis

4.1. Segment Dashboard
4.2. Global AI in Drug Repurposing Market Component Movement Analysis
4.3. Global AI in Drug Repurposing Market Size & Trend Analysis, by Component, 2021 to 2033 (USD Million)
4.4. Software & Platforms
- 4.4.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
4.5. Services
- 4.5.1. Market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 5. AI in Drug Repurposing Market: Technology Estimates & Trend Analysis

5.1. Segment Dashboard
5.2. Global AI in Drug Repurposing Market Technology Movement Analysis
5.3. Global AI in Drug Repurposing Market Size & Trend Analysis, by Technology, 2021 to 2033 (USD Million)
5.4. Machine Learning/Deep Learning
- 5.4.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
5.5. Natural Language Processing (NLP)
- 5.5.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
5.6. Knowledge Graphs & Network-Based AI
- 5.6.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
5.7. Generative AI & Large Language Models (LLMs)
- 5.7.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
5.8. Computer Vision
- 5.8.1. Market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 6. AI in Drug Repurposing Market: Application Estimates & Trend Analysis

6.1. Segment Dashboard
6.2. Global AI in Drug Repurposing Market Application Movement Analysis
6.3. Global AI in Drug Repurposing Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
6.4. Oncology
- 6.4.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
6.5. Neurology
- 6.5.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
6.6. Cardiology
- 6.6.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
6.7. Infectious Diseases
- 6.7.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
6.8. Rare & Orphan Diseases
- 6.8.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
6.9. Other Therapeutic Areas
- 6.9.1. Market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 7. AI in Drug Repurposing Market: End Use Estimates & Trend Analysis

7.1. Segment Dashboard
7.2. Global AI in Drug Repurposing Market End Use Movement Analysis
7.3. Global AI in Drug Repurposing Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
7.4. Pharmaceutical & Biotechnology Companies
- 7.4.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
7.5. Contract Research Organizations (CROs)
- 7.5.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
7.6. Academic & Research Institutes
- 7.6.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
7.7. Others
- 7.7.1. Market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 8. AI in Drug Repurposing Market: Regional Estimates & Trend Analysis

8.1. Regional Market Share Analysis, 2024 & 2033
8.2. Regional Market Dashboard
8.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
8.4. North America
- 8.4.1. U.S.
  - 8.4.1.1. Key country dynamics
  - 8.4.1.2. Regulatory framework
  - 8.4.1.3. Competitive scenario
  - 8.4.1.4. U.S. market estimates and forecasts, 2021 to 2033 (USD Million)
- 8.4.2. Canada
  - 8.4.2.1. Key country dynamics
  - 8.4.2.2. Regulatory framework
  - 8.4.2.3. Competitive scenario
  - 8.4.2.4. Canada market estimates and forecasts, 2021 to 2033 (USD Million)
- 8.4.3. Mexico
  - 8.4.3.1. Key country dynamics
  - 8.4.3.2. Regulatory framework
  - 8.4.3.3. Competitive scenario
  - 8.4.3.4. Mexico market estimates and forecasts, 2021 to 2033 (USD Million)
8.5. Europe
- 8.5.1. UK
  - 8.5.1.1. Key country dynamics
  - 8.5.1.2. Regulatory framework
  - 8.5.1.3. Competitive scenario
  - 8.5.1.4. UK market estimates and forecasts, 2021 to 2033 (USD Million)
- 8.5.2. Germany
  - 8.5.2.1. Key country dynamics
  - 8.5.2.2. Regulatory framework
  - 8.5.2.3. Competitive scenario
  - 8.5.2.4. Germany market estimates and forecasts, 2021 to 2033 (USD Million)
- 8.5.3. France
  - 8.5.3.1. Key country dynamics
  - 8.5.3.2. Regulatory framework
  - 8.5.3.3. Competitive scenario
  - 8.5.3.4. France market estimates and forecasts, 2021 to 2033 (USD Million)
- 8.5.4. Italy
  - 8.5.4.1. Key country dynamics
  - 8.5.4.2. Regulatory framework
  - 8.5.4.3. Competitive scenario
  - 8.5.4.4. Italy market estimates and forecasts, 2021 to 2033 (USD Million)
- 8.5.5. Spain
  - 8.5.5.1. Key country dynamics
  - 8.5.5.2. Regulatory framework
  - 8.5.5.3. Competitive scenario
  - 8.5.5.4. Spain market estimates and forecasts, 2021 to 2033 (USD Million)
- 8.5.6. Norway
  - 8.5.6.1. Key country dynamics
  - 8.5.6.2. Regulatory framework
  - 8.5.6.3. Competitive scenario
  - 8.5.6.4. Norway market estimates and forecasts, 2021 to 2033 (USD Million)
- 8.5.7. Sweden
  - 8.5.7.1. Key country dynamics
  - 8.5.7.2. Regulatory framework
  - 8.5.7.3. Competitive scenario
  - 8.5.7.4. Sweden market estimates and forecasts, 2021 to 2033 (USD Million)
- 8.5.8. Denmark
  - 8.5.8.1. Key country dynamics
  - 8.5.8.2. Regulatory framework
  - 8.5.8.3. Competitive scenario
  - 8.5.8.4. Denmark market estimates and forecasts, 2021 to 2033 (USD Million)
8.6. Asia Pacific
- 8.6.1. Japan
  - 8.6.1.1. Key country dynamics
  - 8.6.1.2. Regulatory framework
  - 8.6.1.3. Competitive scenario
  - 8.6.1.4. Japan market estimates and forecasts, 2021 to 2033 (USD Million)
- 8.6.2. China
  - 8.6.2.1. Key country dynamics
  - 8.6.2.2. Regulatory framework
  - 8.6.2.3. Competitive scenario
  - 8.6.2.4. China market estimates and forecasts, 2021 to 2033 (USD Million)
- 8.6.3. India
  - 8.6.3.1. Key country dynamics
  - 8.6.3.2. Regulatory framework
  - 8.6.3.3. Competitive scenario
  - 8.6.3.4. India market estimates and forecasts, 2021 to 2033 (USD Million)
- 8.6.4. Australia
  - 8.6.4.1. Key country dynamics
  - 8.6.4.2. Regulatory framework
  - 8.6.4.3. Competitive scenario
  - 8.6.4.4. Australia market estimates and forecasts, 2021 to 2033 (USD Million)
- 8.6.5. South Korea
  - 8.6.5.1. Key country dynamics
  - 8.6.5.2. Regulatory framework
  - 8.6.5.3. Competitive scenario
  - 8.6.5.4. South Korea market estimates and forecasts, 2021 to 2033 (USD Million)
- 8.6.6. Thailand
  - 8.6.6.1. Key country dynamics
  - 8.6.6.2. Regulatory framework
  - 8.6.6.3. Competitive scenario
  - 8.6.6.4. Thailand market estimates and forecasts, 2021 to 2033 (USD Million)
8.7. Latin America
- 8.7.1. Brazil
  - 8.7.1.1. Key country dynamics
  - 8.7.1.2. Regulatory framework
  - 8.7.1.3. Competitive scenario
  - 8.7.1.4. Brazil market estimates and forecasts, 2021 to 2033 (USD Million)
- 8.7.2. Argentina
  - 8.7.2.1. Key country dynamics
  - 8.7.2.2. Regulatory framework
  - 8.7.2.3. Competitive scenario
  - 8.7.2.4. Argentina market estimates and forecasts, 2021 to 2033 (USD Million)
8.8. MEA
- 8.8.1. South Africa
  - 8.8.1.1. Key country dynamics
  - 8.8.1.2. Regulatory framework
  - 8.8.1.3. Competitive scenario
  - 8.8.1.4. South Africa market estimates and forecasts, 2021 to 2033 (USD Million)
- 8.8.2. Saudi Arabia
  - 8.8.2.1. Key country dynamics
  - 8.8.2.2. Regulatory framework
  - 8.8.2.3. Competitive scenario
  - 8.8.2.4. Saudi Arabia market estimates and forecasts, 2021 to 2033 (USD Million)
- 8.8.3. UAE
  - 8.8.3.1. Key country dynamics
  - 8.8.3.2. Regulatory framework
  - 8.8.3.3. Competitive scenario
  - 8.8.3.4. UAE market estimates and forecasts, 2021 to 2033 (USD Million)
- 8.8.4. Kuwait
  - 8.8.4.1. Key country dynamics
  - 8.8.4.2. Regulatory framework
  - 8.8.4.3. Competitive scenario
  - 8.8.4.4. Kuwait market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 9. Competitive Landscape

9.1. Company/Competition Categorization
9.2. Strategy Mapping
9.3. Company Market Position Analysis, 2024
9.4. Company Profiles/Listing
- 9.4.1. BostonGene Corporation
  - 9.4.1.1. Company overview
  - 9.4.1.2. Financial performance
  - 9.4.1.3. Product benchmarking
  - 9.4.1.4. Strategic initiatives
- 9.4.2. Ginkgo Bioworks
  - 9.4.2.1. Company overview
  - 9.4.2.2. Financial performance
  - 9.4.2.3. Product benchmarking
  - 9.4.2.4. Strategic initiatives
- 9.4.3. IBM
  - 9.4.3.1. Company overview
  - 9.4.3.2. Financial performance
  - 9.4.3.3. Product benchmarking
  - 9.4.3.4. Strategic initiatives
- 9.4.4. TxGNN
  - 9.4.4.1. Company overview
  - 9.4.4.2. Financial performance
  - 9.4.4.3. Product benchmarking
  - 9.4.4.4. Strategic initiatives
- 9.4.5. BioXcel Therapeutics Inc.
  - 9.4.5.1. Company overview
  - 9.4.5.2. Financial performance
  - 9.4.5.3. Product benchmarking
  - 9.4.5.4. Strategic initiatives
- 9.4.6. BullFrog AI Holdings, Inc.
  - 9.4.6.1. Company overview
  - 9.4.6.2. Financial performance
  - 9.4.6.3. Product benchmarking
  - 9.4.6.4. Strategic initiatives
- 9.4.7. Ignota Labs
  - 9.4.7.1. Company overview
  - 9.4.7.2. Financial performance
  - 9.4.7.3. Product benchmarking
  - 9.4.7.4. Strategic initiatives
- 9.4.8. ISOMORPHIC LABS
  - 9.4.8.1. Company overview
  - 9.4.8.2. Financial performance
  - 9.4.8.3. Product benchmarking
  - 9.4.8.4. Strategic initiatives
- 9.4.9. Insilico Medicine
  - 9.4.9.1. Company overview
  - 9.4.9.2. Financial performance
  - 9.4.9.3. Product benchmarking
  - 9.4.9.4. Strategic initiatives
- 9.4.10. Healx
  - 9.4.10.1. Company overview
  - 9.4.10.2. Financial performance
  - 9.4.10.3. Product benchmarking
  - 9.4.10.4. Strategic initiatives

Product Code: GVR-4-68040-755-3

List of Tables

Table 1 List of abbreviations
Table 2 Global AI in drug repurposing market, by region, 2021 - 2033 (USD Million)
Table 3 Global AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
Table 4 Global AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
Table 5 Global AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
Table 6 Global AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
Table 7 North America AI in drug repurposing market, by country, 2021 - 2033 (USD Million)
Table 8 North America AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
Table 9 North America AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
Table 10 North America AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
Table 11 North America AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
Table 12 U.S. AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
Table 13 U.S. AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
Table 14 U.S. AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
Table 15 U.S. AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
Table 16 Canada AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
Table 17 Canada AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
Table 18 Canada AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
Table 19 Canada AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
Table 20 Mexico AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
Table 21 Mexico AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
Table 22 Mexico AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
Table 23 Mexico AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
Table 24 Europe AI in drug repurposing market, by country, 2021 - 2033 (USD Million)
Table 25 Europe AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
Table 26 Europe AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
Table 27 Europe AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
Table 28 Europe AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
Table 29 UK AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
Table 30 UK AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
Table 31 UK AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
Table 32 UK AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
Table 33 Germany AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
Table 34 Germany AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
Table 35 Germany AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
Table 36 Germany AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
Table 37 France AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
Table 38 France AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
Table 39 France AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
Table 40 France AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
Table 41 Italy AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
Table 42 Italy AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
Table 43 Italy AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
Table 44 Italy AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
Table 45 Spain AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
Table 46 Spain AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
Table 47 Spain AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
Table 48 Spain AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
Table 49 Denmark AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
Table 50 Denmark AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
Table 51 Denmark AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
Table 52 Denmark AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
Table 53 Sweden AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
Table 54 Sweden AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
Table 55 Sweden AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
Table 56 Sweden AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
Table 57 Norway AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
Table 58 Norway AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
Table 59 Norway AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
Table 60 Norway AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
Table 61 Asia Pacific AI in drug repurposing market, by country, 2021 - 2033 (USD Million)
Table 62 Asia Pacific AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
Table 63 Asia Pacific AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
Table 64 Asia Pacific AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
Table 65 Asia Pacific AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
Table 66 China AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
Table 67 China AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
Table 68 China AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
Table 69 China AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
Table 70 Japan AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
Table 71 Japan AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
Table 72 Japan AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
Table 73 Japan AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
Table 74 India AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
Table 75 India AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
Table 76 India AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
Table 77 India AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
Table 78 South Korea AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
Table 79 South Korea AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
Table 80 South Korea AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
Table 81 South Korea AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
Table 82 Australia AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
Table 83 Australia AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
Table 84 Australia AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
Table 85 Australia AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
Table 86 Thailand AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
Table 87 Thailand AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
Table 88 Thailand AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
Table 89 Thailand AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
Table 90 Latin America AI in drug repurposing market, by country, 2021 - 2033 (USD Million)
Table 91 Latin America AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
Table 92 Latin America AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
Table 93 Latin America AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
Table 94 Latin America AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
Table 95 Brazil AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
Table 96 Brazil AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
Table 97 Brazil AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
Table 98 Brazil AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
Table 99 Argentina AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
Table 100 Argentina AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
Table 101 Argentina AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
Table 102 Argentina AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
Table 103 MEA AI in drug repurposing market, by country, 2021 - 2033 (USD Million)
Table 104 MEA AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
Table 105 MEA AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
Table 106 MEA AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
Table 107 MEA AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
Table 108 South Africa AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
Table 109 South Africa AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
Table 110 South Africa AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
Table 111 South Africa AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
Table 112 Saudi Arabia AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
Table 113 Saudi Arabia AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
Table 114 Saudi Arabia AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
Table 115 Saudi Arabia AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
Table 116 UAE AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
Table 117 UAE AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
Table 118 UAE AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
Table 119 UAE AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
Table 120 Kuwait AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
Table 121 Kuwait AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
Table 122 Kuwait AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
Table 123 Kuwait AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)

List of Figures

Fig. 1 Market research process
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Market formulation & validation
Fig. 5 AI in drug repurposing market: Market outlook
Fig. 6 AI in drug repurposing market: Segment outlook
Fig. 7 AI in drug repurposing market: Competitive landscape outlook
Fig. 8 Parent market outlook
Fig. 9 AI in drug repurposing market driver impact
Fig. 10 AI in drug repurposing market restraint impact
Fig. 11 AI in drug repurposing market: Component outlook and key takeaways
Fig. 12 AI in drug repurposing market: Component movement analysis
Fig. 13 Software & platform market estimates and forecasts,2021 - 2033 (USD Million)
Fig. 14 Services market estimates and forecasts,2021 - 2033 (USD Million)
Fig. 15 AI in drug repurposing market: Technology outlook and key takeaways
Fig. 16 AI in drug repurposing market: Technology movement analysis
Fig. 17 Machine learning/deep learning market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 18 Natural language processing (NLP) market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 19 Knowledge graphs & network-based AI market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 20 Generative AI & large language models (LLMs) market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 21 Computer vision market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 22 AI in drug repurposing market: Application outlook and key takeaways
Fig. 23 AI in drug repurposing market: Application movement analysis
Fig. 24 Oncology market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 25 Neurology market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 26 Cardiology market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 27 Infectious diseases market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 28 Rare & orphan diseases market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 29 Other therapeutic areas market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 30 AI in drug repurposing market: End use outlook and key takeaways
Fig. 31 AI in drug repurposing market: End use movement analysis
Fig. 32 Pharmaceutical & biotechnology companies market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 33 Contract research organizations (CROs) market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 34 Academic & research institutes market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 35 Others market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 36 Global AI in drug repurposing market: Regional outlook and key takeaways
Fig. 37 Global AI in drug repurposing market: Regional movement analysis
Fig. 38 North America market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 39 U.S. key country dynamics
Fig. 40 U.S. market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 41 Canada key country dynamics
Fig. 42 Canada market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 43 Mexico key country dynamics
Fig. 44 Mexico market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 45 Europe market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 46 UK key country dynamics
Fig. 47 UK market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 48 Germany key country dynamics
Fig. 49 Germany market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 50 France key country dynamics
Fig. 51 France market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 52 Italy key country dynamics
Fig. 53 Italy market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 54 Spain key country dynamics
Fig. 55 Spain market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 56 Denmark key country dynamics
Fig. 57 Denmark market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 58 Sweden key country dynamics
Fig. 59 Sweden market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 60 Norway key country dynamics
Fig. 61 Norway market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 62 Asia Pacific market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 63 Japan key country dynamics
Fig. 64 Japan market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 65 China key country dynamics
Fig. 66 China market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 67 India key country dynamics
Fig. 68 India market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 69 Thailand key country dynamics
Fig. 70 Thailand market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 71 South Korea key country dynamics
Fig. 72 South Korea market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 73 Australia key country dynamics
Fig. 74 Australia market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 75 Latin America market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 76 Brazil key country dynamics
Fig. 77 Brazil market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 78 Argentina key country dynamics
Fig. 79 Argentina market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 80 Middle East and Africa market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 81 South Africa key country dynamics
Fig. 82 South Africa market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 83 Saudi Arabia key country dynamics
Fig. 84 Saudi Arabia market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 85 UAE key country dynamics
Fig. 86 UAE market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 87 Kuwait key country dynamics
Fig. 88 Kuwait market estimates and forecasts, 2021 - 2033 (USD Million)